Director/PDMR Shareholding

RNS Number : 2632E
Smith & Nephew Plc
09 March 2022
 

SMITH & NEPHEW PLC

 

9 March 2022

 

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

 

1.  VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2010 AND 2020

 

On 7 March 2022, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") vested under the Smith & Nephew Global Share Plan 2010 and 2020.

 

i.  FINAL VESTING ON 7 MARCH 2022 OF 2019 EQUITY INCENTIVE PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:

 

The awards were granted under the Global Share Plan 2010 on 7 March 2019. One third of the Shares vested on 7 March 2020, a further third vested on 7 March 2021 and the final third vested on 7 March 2022. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Final vesting of Equity Incentive Programme awards granted on 7 March 2019 under the Smith & Nephew Global Share Plan 2010.

Date of Transaction

2022 - 03 - 07

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Total Ordinary Share Holding following the transaction *

Total Ordinary Share Holding as a % of the Company's ISC following the transaction *

Helen Barraclough

(Group General Counsel)

PDMR

12.011211

2,417 (of which 1,140 were sold and 1,277 retained)

N/A Single Transaction

18,769.75378 ordinary shares

0.00212%

 

Bradley Cannon

(President, Orthopaedics, Sports Medicine & ENT and Americas)

PDMR

12.011211

4,983 (of which 1,688 were sold and 3,295 retained)

N/A Single Transaction

81,825.17832 ordinary shares (including 2,718.50860 in ADS')

0.00924%

 

Phil Cowdy

(Chief Business Development & Corporate Affairs Officer)

PDMR

12.011211

2,486 (of which 1,173 were sold and 1,313 retained)

N/A Single Transaction

48,446.96621 ordinary shares

0.00547%

Elga Lohler

(Chief HR Officer)

PDMR

12.011211

4,724 (of which 1,851 were sold and 2,873 retained)

N/A Single Transaction

109,689.00000 ordinary shares (including 3,015.00000 in ADS')

0.01239%

 

Vasant Padmanabhan

(President Research & Development)

PDMR

12.011211

4,274 (of which 1,587 were sold and 2,687 retained)

N/A Single Transaction

67307.00000 ordinary shares

0.00760%

 

Susan Swabey

(Company Secretary)

PDMR

12.011211

1,743 (of which 823 were sold and 920 retained)

N/A Single Transaction

50,970.39347 ordinary shares

0.00576%

 

 

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

 

 

ii.  FINAL VESTING ON 7 MARCH 2022 OF SUPPLEMENTARY AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020 FOR THE 2019 PERFORMANCE SHARE PROGRAMME AWARDS:

 

The awards were granted under the Global Share Plan 2020 on 8 March 2021. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards.

 

The following relates to individuals included in the below notification:

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

 

Smith & Nephew plc ordinary shares of USD 0.20 each

 

Identification code

ISIN: GB0009223206

Nature of the transaction

Final vesting on 7 March 2022 of Supplementary Awards granted under the Smith & Nephew Global Share Plan 2020 for the 2019 Performance Share Programme awards .

Date of Transaction

2022 - 03 - 07

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

 

Status

Price (£)

Volume

Aggregated information

Total Ordinary Share Holding following the transaction *

Total Ordinary Share Holding as a % of the Company's ISC following the transaction *

Helen Barraclough

(Group General Counsel)

PDMR

12.011211

3,013 (of which 1,422 were sold and 1,591 retained)

N/A Single Transaction

20,360.75378 ordinary shares

0.00230%

 

Bradley Cannon

(President, Orthopaedics, Sports Medicine & ENT and Americas)

PDMR

12.011211

7,696 (of which 2,607 were sold and 5,089 retained)

N/A Single Transaction

86,914.17832 ordinary shares (including 2,718.50860 in ADS')

0.00982%

 

Phil Cowdy

(Chief Business Development & Corporate Affairs Officer)

PDMR

12.011211

5,641 (of which 2,661 were sold and 2,980 retained)

N/A Single Transaction

51,426.96621 ordinary shares

0.00581%

Simon Fraser

(President, Advanced Wound Management & Global Commercial Operations)

PDMR

12.011211

6,791 (of which 2,021 were sold and 4,770 retained)

N/A Single Transaction

15,433.59428 ordinary shares

0.00174%

 

Elga Lohler

(Chief HR Officer)

PDMR

12.011211

6,680 (of which 2,626 were sold and 4,054 retained)

N/A Single Transaction

113,743.00000 ordinary shares (including 3,015.00000 in ADS')

0.01285%

 

Vasant Padmanabhan

(President Research & Development)

PDMR

12.011211

6,595 (of which 2,449 were sold and 4,146 retained)

N/A Single Transaction

71,453.00000 ordinary shares

0.00807%

 

Susan Swabey

(Company Secretary)

PDMR

12.011211

2,446 (of which 1,154 were sold and 1,292 retained)

N/A Single Transaction

52,262.39347 ordinary shares

0.00590%

 

 

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

 

 

2.  PHIL COWDY - SALE OF ORDINARY SHARES

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Smith & Nephew plc ordinary shares of USD 0.20 each

Identification code

ISIN: GB0009223206

Nature of the transaction

Sale of ordinary shares.

Date of Transaction

2022 - 03 - 08

Place of Transaction

London Stock Exchange (XLON)

 

Name (Position)

Director / PDMR

Price (£)

Volume

Aggregated information

Total Ordinary Share Holding following the transaction *

Total Ordinary Share Holding as a % of the Company's ISC following the transaction *

Phil Cowdy

(Chief Business Development & Corporate Affairs Officer)

PDMR

11.793781

4,293

N/A Single Transaction

47,133.96621 ordinary shares

0.00532%

 

* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.

 

 

Sarah Carne

Deputy Company Secretary

Smith & Nephew plc

 

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFEDVAIAIIF
UK 100

Latest directors dealings